AVEO
Pharmaceuticals Inc. (Nasdaq: AVEO) entered an exclusive worldwide
license
agreement for Novartis (NYSE: NVS) to develop and commercialize AV-380.
Shares of AVEO soared 58 cents to $1.75 while Novartis stock rose 69 cents to $103.17.
AVEO enters license agreement with Novartis
August 17, 2015 at 07:39 AM EDT
